The FDA has proposed a rule that would introduce mandatory GRAS notification for companies marketing food ingredients under the Generally Recognized as Safe (GRAS) provision. If finalized, this change would end the decades-old practice of allowing companies to determine GRAS status on their own, without ever telling the FDA.
For food and ingredient companies, this is a meaningful shift. Since 1997, GRAS notification has been voluntary, which means many ingredients have entered the U.S. food supply without FDA ever reviewing the basis for their GRAS status.
The new proposal, published for public inspection on August 11, 2026, would change that by requiring formal notification for most ingredients relying on a GRAS conclusion.
Why FDA Is Proposing This Change
According to the proposed rule published in the Federal Register, FDA has identified real gaps in its oversight under the voluntary system. The agency points to several cases where a lack of information caused delays in addressing safety concerns, including the continued marketing of caffeinated alcoholic beverages, unapproved Delta-8 THC food products, and tara flour, which was linked to hundreds of adverse event reports before FDA learned the product had never been the subject of a GRAS notice.
FDA also notes that its understanding of the food supply has not kept pace with its complexity. As of 2011, estimates suggested more than 10,000 additives were in use in food, including roughly 1,000 substances marketed based on independent GRAS conclusions that were never shared with the agency.
Because notification has been optional, FDA often has no visibility into these substances until a public health issue surfaces.
What Mandatory GRAS Notification Would Require
Under the proposed rule, any company introducing a substance into interstate commerce under the GRAS provision would need to notify FDA of the basis for its GRAS conclusion, unless a specific exception applies. This would apply to ingredients already in the food supply as well as new ones entering the market for the first time.
The rule also proposes a one-time, time-limited pathway for substances already on the market. Companies that have relied on an independent GRAS conclusion in the past would be able to submit a streamlined notification within one year of the rule’s effective date, rather than preparing a full GRAS notice from scratch. This option would require less information than a standard notice, though FDA could still request a full GRAS notice later if questions arise.
Exceptions to the Notification Requirement
Not every ingredient would need a new submission. The proposed rule outlines several exceptions, including substances already covered by an existing no questions letter, ingredients listed or affirmed as GRAS in FDA’s regulations, and substances that qualify for a Threshold of Regulation exemption. Ingredients evaluated through certain established FDA consultation processes, such as premarket biotechnology consultations, would also be excepted if FDA’s public documentation for that process does not call for a GRAS notice.
These exceptions matter because they determine which companies face new obligations and which can rely on existing determinations. Reviewing your ingredient portfolio against these categories now, well ahead of any final rule, can help you understand where you stand.
Proposed Timeline
FDA proposes that any final rule take effect 60 days after publication, with an 18-month compliance period before mandatory notification becomes enforceable. The one-year window for the streamlined, transitional submission option would run concurrently with that compliance period. The public comment period on the proposed rule is open for 120 days from the date of publication, giving stakeholders an opportunity to weigh in before the rule is finalized.
What This Means for Your Business
If your company currently relies on an independent GRAS conclusion, meaning you determined an ingredient was GRAS without submitting a notice to FDA, this proposal is worth your attention. A mandatory GRAS notification requirement would mean gathering and organizing the scientific basis for that conclusion, potentially years after the original determination was made.
Companies that already hold a no questions letter from FDA are in a stronger position, since that letter would generally exempt the covered use from the new requirement. For everyone else, now is a good time to take stock of which ingredients might need a first-time GRAS notice or a streamlined submission once the rule takes effect.
Frequently Asked Questions
Does this mean my ingredient is no longer GRAS?
No. The proposed rule does not change which substances qualify as GRAS. It changes whether companies must tell FDA about their GRAS conclusion. An ingredient that is genuinely safe under its intended conditions of use remains GRAS regardless of notification status.
Is mandatory GRAS notification already in effect?
Not yet. This is a proposed rule, not a final one. FDA is accepting public comments for 120 days after publication, and the requirement would only take effect after a final rule is issued, followed by an 18-month compliance period.
Can I still market a product while my GRAS notice is under review?
Yes. The proposed rule does not create a premarket approval requirement. Companies could continue marketing a product with a purported GRAS status before FDA files or evaluates the related notice.
Will I have time to prepare if this rule is finalized?
Yes. Between the 60-day effective date, the 18-month compliance period, and the one-year window for streamlined submissions on existing ingredients, companies would have a meaningful runway to review their GRAS documentation and prepare submissions.
Key Takeaways
- FDA has proposed converting the voluntary GRAS notification program into a mandatory one, requiring most companies to formally notify FDA of their GRAS conclusions.
- A one-year, streamlined submission option would be available for substances already marketed under an independent GRAS conclusion.
- Several exceptions exist, including existing no questions letters and ingredients already listed or affirmed as GRAS in FDA regulations.
- The public comment period runs for 120 days from publication, with an 18-month compliance period proposed after the rule is finalized.
- Companies relying on unreported GRAS conclusions should begin reviewing their documentation now.
Preparing for Mandatory GRAS Notification
Regulatory proposals like this one can be dense, and the exceptions in particular require a careful read against your specific ingredients and their conditions of use. If you want help reviewing where your products stand under the proposed rule, or preparing documentation for a future GRAS notice, contact our team to discuss your next steps.
